Browse the evidence

Tirzepatide facilitates significant weight loss and improves lipid profiles in individuals with spinal cord injury (SCI) who are refractory to standard dietary and exercise interventions.

If you have a spinal cord injury and have tried strict diet and exercise without success, ask your doctor about tirzepatide. It is a weekly injection that helped this patient lose 33 pounds and improve his cholesterol, even when standard lifestyle changes failed. Be aware that GI side effects are possible, though this patient tolerated them well.

Consuming protein immediately before resistance training may increase lower body (leg press) strength gains more than consuming it immediately after.

If you are focusing on leg strength, try eating your protein 15 minutes before your workout. This might give you a slight edge in strength gains compared to drinking it after, possibly because it provides fuel for your legs. However, this finding is based on very limited data, so don't stress if you can't make it work.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce major adverse cardiovascular events (MACE) in non-diabetic adults with obesity, with benefits occurring through both weight-loss-dependent and independent mechanisms.

If you have obesity and are not diabetic, GLP-1 medications like semaglutide or liraglutide can significantly lower your risk of heart attack, stroke, and heart failure. This benefit is not just from losing weight; the drugs also directly protect your blood vessels and heart. While side effects like nausea are common, they are usually manageable with slow dose increases and dietary changes. For those who dislike injections, oral versions are also effective.

Tirzepatide (10-15 mg weekly) produces significantly greater total weight loss (-20.2%) compared to Semaglutide (1.7-2.4 mg weekly, -13.7%) in obese patients, as demonstrated in the SURMOUNT-5 trial.

If you are struggling with obesity and other medications have failed, Tirzepatide (10-15 mg weekly) offers superior weight loss compared to Semaglutide. Discuss this dual-agonist option with your doctor, especially if you have not achieved sufficient weight loss with other GLP-1 treatments.

Consuming 30g of protein from lean beef immediately following resistance training may augment chronic adaptations in strength and lean tissue accretion compared to a placebo, though its efficacy relative to whey protein remains to be determined by this ongoing trial.

This study is currently a protocol and has not yet published results. However, it suggests that consuming ~30g of protein from lean beef immediately after resistance training is a viable strategy to potentially enhance strength and muscle gains. If you prefer whole foods over supplements, lean beef is a high-quality source of protein and micronutrients. Ensure you are doing consistent resistance training (3x/week) and consuming this protein within an hour post-workout.

Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) reduce HbA1c, fasting plasma glucose, and body weight in Type 2 Diabetic athletes, but pose risks of hypovolemia, dehydration, and euglycemic DKA.

If you take SGLT2 inhibitors (like empagliflozin or dapagliflozin) for Type 2 Diabetes, you will likely lose weight and improve your blood sugar control. However, these drugs make you urinate more, which can lead to dehydration and dizziness during exercise. Drink extra water, watch for signs of low blood pressure, and be aware of the rare risk of euglycemic DKA (diabetic ketoacidosis with normal blood sugar).

Integrating intermittent Continuous Glucose Monitoring (CGM) with culturally-informed kaiāwhina support and optimized clinical care significantly reduces HbA1c levels in patients with Type 2 Diabetes compared to usual care.

For patients with Type 2 Diabetes who struggle with standard care, combining continuous glucose monitoring (CGM) with culturally tailored support (kaiāwhina) and optimized medical management can significantly improve blood sugar control. This approach addresses both the technical aspect of glucose tracking and the social/cultural barriers to care.

A 36-month complex lifestyle intervention combining digital tools, face-to-face group education, and individual consultations significantly reduces the incidence of type 2 diabetes in adults with prediabetes compared to usual care.

If you have prediabetes, a structured program combining regular group education, personal coaching, and digital tracking over 3 years is designed to help you lose weight, eat healthier, and exercise more to prevent diabetes. This approach is more comprehensive than digital tools alone.

Intensive lifestyle interventions, specifically achieving significant weight loss (≥10-15 kg or ≥10% body weight), can induce Type 2 Diabetes (T2DM) remission in overweight or obese patients by correcting insulin resistance and restoring beta-cell function.

If you have Type 2 Diabetes and are overweight, losing a significant amount of weight (at least 10-15 kg) through a structured diet and exercise program can potentially put your diabetes into remission. This means your blood sugar levels may return to normal without medication. However, this requires a strong commitment to maintaining that weight loss, as the condition can return if weight is regained. Consult a doctor to see if you are a candidate, especially if your diabetes was recently diagnosed.

Tirzepatide (5, 10, or 15 mg weekly) produces superior, dose-dependent weight loss and glycemic improvements compared to insulin and GLP-1 receptor agonists in adults with type 2 diabetes and/or obesity.

Tirzepatide is currently the most potent pharmacological therapy for weight loss and blood sugar control in type 2 diabetes and obesity, outperforming both insulin and other GLP-1 drugs. It works by mimicking two gut hormones (GIP and GLP-1) to reduce appetite and improve insulin sensitivity. While effective, it carries a higher risk of gastrointestinal side effects like nausea compared to other treatments.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss (up to 20.9% with 15 mg weekly dose) and is recommended for patients targeting 15-20% weight loss.

If you need to lose a significant amount of weight (15-20%), ask your doctor about tirzepatide. It is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1). Start at a low dose to minimize side effects, and gradually increase it over several months to find the right dose for you. It is more potent than older GLP-1 drugs.

CagriSema (semaglutide + cagrilintide) produces superior weight loss (22.7% at 68 weeks) compared to semaglutide 2.4 mg alone (16.1%) or cagrilintide alone (11.8%).

If you have obesity and need maximum weight loss, ask your doctor about CagriSema. It combines two hormones (GLP-1 and amylin) into one weekly injection. Clinical trials show it can help you lose nearly 23% of your body weight, which is more than semaglutide or tirzepatide alone. It is currently in Phase 3 trials.

A 1-year person-centered and culturally sensitive intervention, including continuous glucose monitoring and extended healthcare professional consultations, improves glycemic control (HbA1c) and diabetes management in non-Western, Arabic-, Turkish-, or Urdu-speaking individuals with Type 2 Diabetes compared to usual care.

For individuals with Type 2 Diabetes from Arabic, Turkish, or Urdu-speaking backgrounds, standard care may not be enough. This protocol suggests seeking a specialized, culturally sensitive program that includes continuous glucose monitoring, extended consultations with the same healthcare team, and education in your native language. This approach aims to improve blood sugar control and overall well-being by addressing language barriers and cultural needs.

Cohabiting with a partner receiving tirzepatide pharmacotherapy can induce significant weight loss and metabolic improvement in an untreated spouse through vicarious efficacy driven by shared environmental and behavioral changes.

If you are starting tirzepatide and live with a partner who has metabolic issues, your changes to food shopping and cooking habits may significantly benefit them too. Encourage your partner to monitor their health metrics, as they may see improvements in weight and blood sugar without needing medication themselves. Discuss these changes openly to ensure both partners are comfortable with the household shifts.

Tirzepatide use, particularly with unsupervised dose escalation and caloric restriction, can cause euglycemic ketoacidosis (EKA) in non-diabetic patients.

If you are using tirzepatide, do not self-prescribe or self-escalate doses. Monitor for signs of metabolic acidosis (nausea, vomiting, abdominal pain, fatigue) especially if you are eating very little. Seek immediate medical attention if these symptoms occur, as they can signal euglycemic ketoacidosis, a rare but serious condition.

Tirzepatide treatment in premenopausal women with obesity is hypothesized to increase brown adipose tissue (BAT) volume and activity and induce white adipose tissue (WAT) browning, potentially mitigating the decline in resting energy expenditure typically associated with weight loss.

This paper outlines a clinical trial design, not a consumer guide. It hypothesizes that tirzepatide may help maintain metabolic rate during weight loss by activating brown fat and turning white fat 'beige'. The protocol involves weekly injections starting at a low dose and slowly increasing over 24 weeks, with close monitoring for side effects. No results are available yet.

SGLT2 inhibitors and GLP-1 receptor agonists provide multi-organ cardiorenal protection beyond glycemic control, with selection prioritized by phenotype (e.g., SGLT2i for heart failure/CKD, GLP-1RA for ASCVD/obesity).

If you have heart, kidney, or metabolic issues, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These drugs protect your heart and kidneys, not just your blood sugar. Your doctor might even be able to lower your doses of other blood pressure or diabetes pills, reducing your risk of side effects like low blood sugar or dizziness.

Non-steroidal mineralocorticoid receptor antagonists (ns-MRA) like finerenone reduce cardiovascular and renal risks in T2D+CKD patients, with hyperkalemia risk manageable through monitoring.

If you have diabetes and kidney disease, ask about finerenone. It protects your heart and kidneys. Your doctor will check your potassium levels regularly to ensure it is safe for you.

Tirzepatide treatment, particularly during dose escalation, is associated with an increased risk of acute duodenal ulcer perforation in patients with pre-existing untreated Helicobacter pylori infection.

If you are taking tirzepatide and experience persistent or worsening stomach pain, nausea, or vomiting that does not resolve, do not assume it is just a normal side effect. Seek medical attention immediately, especially if you have a history of stomach issues or H. pylori. Early detection of ulcers can prevent perforation.

High-dose tirzepatide (15 mg weekly) can induce severe gastrointestinal side effects (prolonged vomiting and diarrhea) leading to profound electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia), which precipitate life-threatening ventricular fibrillation and cardiac arrest.

If you are on 15mg tirzepatide and have persistent vomiting or diarrhea, do not ignore it. Ask your doctor to check your potassium, magnesium, and calcium levels immediately. Severe GI loss can trigger dangerous heart rhythms even if you have no prior heart history.

Evidence regarding the impact of GLP-1 RAs on total shoulder arthroplasty (TSA) outcomes is limited, heterogeneous, and contradictory, with some studies showing reduced mortality and adverse events while others show increased complications.

For shoulder replacement surgery, the data on GLP-1 RAs is mixed. Some studies show benefits like lower mortality, while others show higher risks of blood clots and pneumonia. Because the evidence is weak and contradictory, your surgical team will likely evaluate your specific case carefully. Do not assume the benefits seen in hip/knee surgery apply here without explicit guidance from your surgeon.

Metabolic surgery (bariatric surgery) is a highly effective treatment for T2DM remission in patients with BMI ≥ 32.5 kg/m2, offering higher remission rates and long-term benefits compared to conventional treatments.

If you have Type 2 Diabetes and a high BMI (32.5 or higher), and lifestyle changes haven't been enough, metabolic surgery might be an option. It can lead to long-term remission of diabetes for many people. Discuss with your doctor if you are a candidate, as it involves surgery and long-term monitoring.

Adherence to a nutrient-dense carnivore diet (high fat, moderate protein, negligible carbohydrates) can induce remission of type 2 diabetes and hypertension in patients with long-standing disease history.

This case suggests that eliminating carbohydrates and eating a diet consisting only of animal products (meat, eggs, fats) may help reverse type 2 diabetes and hypertension, even in long-standing cases. However, this is based on a single patient who also had cancer and refused standard care. Do not attempt this without medical supervision, especially if you have kidney disease or are on medication, as dosages may need adjustment.

In patients with type 2 diabetes and high cardiovascular risk (CAC ≥ 100), intensified multifactorial treatment using SGLT2 inhibitors and GLP-1 receptor agonists combined with high-intensity lipid-lowering therapy reduces cardiovascular events compared to standard treatment.

If you have Type 2 Diabetes and a high Coronary Artery Calcification (CAC) score (≥100), current standard care may not be enough. This trial tests whether adding specific heart-protective diabetes medications (SGLT2 inhibitors and GLP-1 agonists) along with aggressive cholesterol and blood pressure management significantly reduces your risk of heart attack, stroke, or heart failure compared to standard care. You should discuss your CAC score and whether intensified therapy is appropriate for your specific risk profile with your doctor.